BioCentury | May 26, 2017
Finance

Europe’s bellwether challenge

...The other two were British Biotech plc , which infamously imploded in 1998, and Celltech...
...in 2006 • Lack of internal R&D • Distraction by patent battle with MorphoSys AG Celltech...
BioCentury | Jul 21, 2016
Strategy

Brexit of brains

...but were taken out via M&A, blunting the growth of the ecosystem. Most notable were Celltech...
...and Cambridge Antibody Technology Group plc, which held promise of serving as biotech bellwethers. But Celltech...
BioCentury | Jun 27, 2016
Finance

Nine lives?

...the funk lasted for at least five years. The next heir to the throne was Celltech...
...market cap climb from $591 million in June 1999 to $1.4 billion in early 2003. Celltech...
...anchor company when it was taken out by UCB Group in 2004. UCB Group acquired Celltech...
BioCentury | Dec 24, 2012
Strategy

The deCoding of Amgen

...Celltech Group plc and Amgen partnered to research, develop and commercialize osteoporosis therapies targeting sclerostin. Celltech...
BioCentury | Dec 19, 2011
Clinical News

Mylotarg gemtuzumab ozogamicin: Phase III data

...treat relapsed AML. Mylotarg was co-developed by Wyeth , which was acquired by Pfizer, and Celltech plc...
BioCentury | Dec 2, 2011
Politics & Policy

EU court ruling clarifies SPCs for combo products

...supporting marketing authorization covered a product with nine ingredients. Medeva was acquired in 2000 by Celltech...
BioCentury | Jan 10, 2011
Company News

Symphogen board of directors update

...Symphogen A/S , Copenhagen, Denmark Business: Antibodies Appointed: Goran Ando as chairman, previously CEO of Celltech...
BioCentury | Jan 7, 2011
Top Story

Symphogen raises EUR 100 million

...also participated. Symphogen also appointed Goran Ando as chairman. Ando is the former CEO of Celltech...
BioCentury | Dec 20, 2010
Strategy

TAP's Big Finish

...up front from adding additional antigens Up to $1.4B under Aug 2010 amended deal 2002 Celltech...
BioCentury | Jun 28, 2010
Clinical News

Mylotarg gemtuzumab ozogamicin regulatory update

...said the withdrawal will be effective Oct. 15. Mylotarg was co-developed by Wyeth and Celltech plc...
Items per page:
1 - 10 of 583
BioCentury | May 26, 2017
Finance

Europe’s bellwether challenge

...The other two were British Biotech plc , which infamously imploded in 1998, and Celltech...
...in 2006 • Lack of internal R&D • Distraction by patent battle with MorphoSys AG Celltech...
BioCentury | Jul 21, 2016
Strategy

Brexit of brains

...but were taken out via M&A, blunting the growth of the ecosystem. Most notable were Celltech...
...and Cambridge Antibody Technology Group plc, which held promise of serving as biotech bellwethers. But Celltech...
BioCentury | Jun 27, 2016
Finance

Nine lives?

...the funk lasted for at least five years. The next heir to the throne was Celltech...
...market cap climb from $591 million in June 1999 to $1.4 billion in early 2003. Celltech...
...anchor company when it was taken out by UCB Group in 2004. UCB Group acquired Celltech...
BioCentury | Dec 24, 2012
Strategy

The deCoding of Amgen

...Celltech Group plc and Amgen partnered to research, develop and commercialize osteoporosis therapies targeting sclerostin. Celltech...
BioCentury | Dec 19, 2011
Clinical News

Mylotarg gemtuzumab ozogamicin: Phase III data

...treat relapsed AML. Mylotarg was co-developed by Wyeth , which was acquired by Pfizer, and Celltech plc...
BioCentury | Dec 2, 2011
Politics & Policy

EU court ruling clarifies SPCs for combo products

...supporting marketing authorization covered a product with nine ingredients. Medeva was acquired in 2000 by Celltech...
BioCentury | Jan 10, 2011
Company News

Symphogen board of directors update

...Symphogen A/S , Copenhagen, Denmark Business: Antibodies Appointed: Goran Ando as chairman, previously CEO of Celltech...
BioCentury | Jan 7, 2011
Top Story

Symphogen raises EUR 100 million

...also participated. Symphogen also appointed Goran Ando as chairman. Ando is the former CEO of Celltech...
BioCentury | Dec 20, 2010
Strategy

TAP's Big Finish

...up front from adding additional antigens Up to $1.4B under Aug 2010 amended deal 2002 Celltech...
BioCentury | Jun 28, 2010
Clinical News

Mylotarg gemtuzumab ozogamicin regulatory update

...said the withdrawal will be effective Oct. 15. Mylotarg was co-developed by Wyeth and Celltech plc...
Items per page:
1 - 10 of 583